Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2025 financial and ...

The melanoma market is predicted to surge during the forecast period (2025–2034) owing to factors, as the increasing incidence of melanoma, the launc ...

As usual, the one-two punch of ASCO and BIO set us a bit behind, but never fear – your June hires round-up is here at least ...

Bristol Myers Squibb (BMY) ended the recent trading session at $48.02, demonstrating a +2.85% change from the preceding day's closing price. The stock outperformed the S&P 500, which registered a ...

Bristol-Myers Squibb recently wrapped up a pivotal study in Japan, focusing on the quality of life in patients with ...

Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

The Cancer Immunotherapy market, valued at USD 220.94 billion in 2024, is expected to register robust revenue CAGR of 13.6%.

Jim Cramer, a stalwart of stock market commentary, recently shifted gears on Bristol-Myers Squibb, pegging his hopes on their ...

An oral neutrophil modulator appeared safe and demonstrated signals of efficacy in patients with moderate to severe ...

Explore the comprehensive Pulmonary Arterial Hypertension (PAH) market forecast, covering 68 global markets. From $10.1 billion in 2024 to $17.9 billion by 2034, the 7 major markets lead with 48% ...

The Global Bladder Cancer Market was valued at USD 4.4 Billion in 2024, and it is expected to reach USD 7.2 Billion by 2035, ...